Levact (Bendamustine Hydrochloride)

Bendamustine exerts its effect by forming covalent bonds with DNA, creating cross‑links that block replication and transcription. This DNA damage triggers programmed cell death (apoptosis) preferentially in rapidly dividing cancer cells, thereby reducing tumor burden.

The dosing regimen for Levact is individualized by the prescribing oncologist based on the specific indication, patient weight, renal and hepatic function, and treatment protocol. Exact dose and schedule should be determined by a qualified healthcare professional.

Bendamustine may cause fetal harm and its safety in pregnancy has not been established. Women of childbearing potential should use effective contraception during treatment and for a defined period afterward. Breastfeeding is not recommended while receiving bendamustine therapy.

To place an order, submit an enquiry on the Levact product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with other alkylating agents such as cyclophosphamide, bendamustine offers a distinct mechanism that combines alkylation with a benzimidazole ring, potentially providing higher response rates in certain B‑cell malignancies. However, therapeutic choice depends on disease characteristics, prior therapies, and patient tolerance.

Levact should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and discoloration, and prepared according to aseptic technique.

Levact is supplied as an intravenous solution that is infused slowly into a peripheral or central vein under controlled conditions. Administration is typically performed by trained medical staff in an oncology clinic or hospital setting, with monitoring for infusion‑related reactions.

The most serious risks include severe myelosuppression leading to infections, pulmonary toxicity such as interstitial pneumonitis, and the potential development of secondary malignancies. Patients should be closely monitored for signs of infection, respiratory symptoms, and abnormal blood counts throughout therapy.

Levact is contraindicated in patients with known hypersensitivity to bendamustine or any of its excipients. It should also be avoided in individuals with active uncontrolled infections, severe hepatic impairment, or those receiving live vaccines due to the risk of severe immunosuppression.